I-86 (1812) i-4514114 info@phcoker.com

I-Avanafil powder emifushane (330784-47-9)

I-Avanafil powder isetshenziselwa ukwelapha abesilisa abanokungasebenzi (okubizwa nangokuthi ukungabi namandla kocansi). I-Avanafil ingeqembu le …………… ..


Isimo: Ekukhiqizeni kweMisa
Iyunithi: 25kg / Drum
Umthamo: 1290kg / inyanga

Incazelo

I-Avanafil powder emfushane (i-330784-47-9) ividiyo

I-Avanafil powder emfushane (330784-47-9) Incazelo

I-Raw Avanafil powder yi-PDE5 inhibitor evunyelwe ukungasebenzi (i-ED: ukungabi namandla; ukungakwazi ukuthola noma ukugcina indalo emadodeni). I-Raw Avanafil powder isebenza ngokuvimbela uhlobo oluthile lwe-phosphodiesterase uhlobo lwe-5 enzyme etholakala kwezicubu zomzimba ezahlukahlukene, kepha ikakhulukazi kwi-corpus cavernosum penis, kanye ne-retina. Isebenza ngokwandisa ukugeleza kwegazi kuya esinyeni ngesikhathi sokuvuselelwa kocansi. Ezinye izidakamizwa ezifanayo yi-sildenafil, tadalafil ne-vardenafil. Inzuzo ye-Raw Avanafil powder ukuthi inokushesha okusheshayo kwesenzo kuqhathaniswa nezinye i-PDE5 inhibitors. Iyangenwa masinyane, ifinyelela ekuhlushweni okuphezulu cishe ngamaminithi we-30-45.Ngxenye yesibili yababambe iqhaza ikwazile ukwenza ucansi kungakapheli imizuzu eyi-15.

I-Avanafil powder emifushane (330784-47-9) Siziqu

Igama Product I-Avanafil enamandla
Igama leKhemikhali 330784-47-9;STENDRA; (s)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790; TA-1790
Brand NAme U-Stendra no-Spedra
I-Drug Class I-PDE5 inhibitor
CAS Inombolo 330784-47-9
InChIKey I-WEAJZXNPAWBCOA-INIZCTEOSA-N
I-molecular Fi-ormula C23H26ClN7O3
I-molecular Weziyisishiyagalombili 483.95
IMisa ye-Monoisotopic I-483.179 g / mol
Ukuxuba Pi-oint I-150-152 ° C
Fukuvuselela kabusha Pi-oint Ayikho idatha etholakalayo
I-Half Half-Life Isilinganiso sokuqeda isigamu-impilo = 5.36 - amahora we-10.66
ukubukeka powder emhlophe
Sukufaneleka I-DMSO, i-Methanol
Sukuhlushwa Tukushisa Gcina ku-4 ° C
Isicelo I-phosphodiesterase (PDE5) inhibitor, esetshenziselwa ukwelapha ukungasebenzi kahle.

I-Avanafil powder emfushane (330784-47-9) Incazelo

I-Avanafil isetshenziselwa ukwelapha ukungasebenzi kahle (i-ED: ukungabi namandla; ukungakwazi ukuthola noma ukugcina indalo emadodeni). I-Avanafil powder isesigabeni semithi esibizwa nge-phosphodiesterase (PDE) inhibitors. Isebenza ngokwandisa ukugeleza kwegazi kuya esinyeni ngesikhathi sokuvuselelwa kocansi. Ukugeleza kwegazi okwandisiwe kungadala ukwakheka. I-Avanafil powder ayelaphe ukungasebenzi noma ikhulise isifiso sobulili. I-Avanafil ayikuvimbeli ukukhulelwa noma ukusakazeka kwezifo ezithathelwana ngocansi njengegciwane lesifo sokugonywa komuntu (i-HIV).

I-Avanafil powder (330784-47-9) Indlela Yokusebenza

I-Avanafil iyi-enzymme ye-phosphodiesterase ekhethekile ye-5 (PDE5) esetshenziselwa ukwelapha ukungasebenzi kahle okubangelwa isifo sikashukela, iminyaka yokuxineka oxidative noma ezinye izinkinga. I-Avanafil ivimbela uhlobo lwe-cGMP oluthile lwe-phosphodiesterase 5 (PDE5) elibhekele ukucekelwa phansi kwe-cGMP endaweni ye-corpus cavernosum etholakala ezungeze ipipi. I-penile erection ngesikhathi sokuvuselela ucansi ibangelwa ukukhuphuka kwegazi kwe-penile okuvela ekuphumuleni kwemithambo ye-penile kanye ne-corpus cavernosal imisipha ebushelelezi. Le mpendulo iqondiswa ngokukhishwa kwe-nitric oxide (NO) ezikhungweni zezinzwa namaseli endothelial, okuvuselela ukuhlanganiswa kwe-cGMP kumaseli abushelelezi bemisipha. I-cyclic GMP ibangela ukuphumula kwemisipha ebushelelezi futhi yandise ukuphuma kwegazi ku-corpus cavernosum. Ukuvinjelwa kohlobo lwe-phosphodiesterase 5 (PDE5) yi-avanafil kuthuthukisa umsebenzi ngokwandisa inani le-cGMP.

Isicelo se-Avanafil powder (330784-47-9)

I-Avanafil powder isetshenziselwa ukwelapha abesilisa abanokungasebenzi (okubizwa nangokuthi ukungabi namandla kocansi).

Kunconywe i-Avanafil powder (330784-47-9) Isilinganiso

Kubantu abaningi, isisindo sokuqala sokuphakanyiswa kwe-avanafil powder ngu-100 mg ngosuku oluthathwa ngamaminithi we-30 ngaphambi kocansi. Ngokuya ngokwanele kwempendulo noma imiphumela emibi, umthamo unganyuka ube yi-200 mg noma wehla ku-50 mg ngosuku. Abantu abaphuza imithi yokwandisa amazinga ka-avanafil ngokwemvelo akufanele kudlule inani elilodwa lama-50 mg kumahora angu-24 (Bheka ukusebenzisana kwezidakamizwa).

Izinzuzo ze-Avanafil powder (330784-47-9)

Yeka ukusebenzisa i-avanafil bese ushayela udokotela wakho kanyekanye uma unayo:

▪ izinguquko zombono, ukulahleka komqondo ngokuzumayo;

▪ ukukhala ezindlebeni zakho, noma ukulahlekelwa okungazelelwe;

▪ ubuhlungu, ukuvuvukala, ukufudumala, noma ukubomvu komunye owodwa noma emilenzeni yombili;

▪ ukuphefumula, ukuvuvukala ezandleni noma ezinyaweni;

▪ umuzwa ohlose ukukhanya, njengokungathi ungadlula; noma

▪ i-penis erection ebuhlungu noma ihlala amahora we-4 noma ngaphezulu.

Imiphumela emibi evamile ingafaka:

▪ ikhanda;

▪ ukufudumala (ukufudumala, ukubomvu, noma ukuzwa okunamahloni);

▪ izimpawu ezibandayo ezifana ne-runny noma i-nosey stuffy, emqaleni; noma

▪ ubuhlungu emuva.


=

Okubhekiselweyo nokuhlungwa komkhiqizo

Imibuzo ye-9 ukuzibuza ngaphambi kokuthatha u-Avanafil

Okubhekwayo

  1. URyan M Burke, uJeffery D Evans, i-Avanafil ekwelapheni ukungasebenzi kahle kwezomzimba: ukubukeza amandla ayo, i-Vasc Health Risk Manag. I-2012; I-8: 517-523.
  2. I-DeRogatis LR, uBurnett AL. I-epidemiology yezidakamizwa zobulili. I-J Med Med. 2008; 5: 289-300.
  3. UZhao C, Kim S, Yan D, et al. Ukusebenza ngokuphepha nokuphepha kwe-avanafil ekwelapheni ukungasebenzi kahle: imiphumela yokuhlolwa okune-multicentre, okuhleliwe, izimpumputhe ezibili, kanye nokulawulwa kwe-placebo. BJU Int. I-2012 Mar 27;

I-Shangke Chemical yinkampani ephezulu echwepheni ezisebenzayo ezizimele eziphambili zokwelapha (APIs). Ukuze ulawule ikhwalithi ngesikhathi sokukhiqiza, inqwaba yabachwepheshe abanolwazi, imishini yokukhiqiza yokuqala kanye nama-laboratories yiwona amaphuzu ayisihluthulelo.

Xhumana nathi